Iovance Biotherapeutics (IOVA) Competitors

$11.86
+0.54 (+4.77%)
(As of 04/23/2024 ET)

IOVA vs. IBRX, SWTX, APGE, ACLX, IMCR, CGON, DNLI, VCEL, IMVT, and BEAM

Should you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include ImmunityBio (IBRX), SpringWorks Therapeutics (SWTX), Apogee Therapeutics (APGE), Arcellx (ACLX), Immunocore (IMCR), CG Oncology (CGON), Denali Therapeutics (DNLI), Vericel (VCEL), Immunovant (IMVT), and Beam Therapeutics (BEAM). These companies are all part of the "biological products, except diagnostic" industry.

Iovance Biotherapeutics vs.

Iovance Biotherapeutics (NASDAQ:IOVA) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.

Iovance Biotherapeutics presently has a consensus target price of $24.64, suggesting a potential upside of 117.64%. ImmunityBio has a consensus target price of $5.00, suggesting a potential upside of 1.21%. Given Iovance Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Iovance Biotherapeutics is more favorable than ImmunityBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iovance Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
3.00
ImmunityBio
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Iovance Biotherapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Iovance Biotherapeutics has higher revenue and earnings than ImmunityBio. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iovance Biotherapeutics$1.19M2,656.97-$444.04M-$1.88-6.02
ImmunityBio$620K5,394.16-$583.20M-$1.16-4.26

Iovance Biotherapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -93,761.41%. ImmunityBio's return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Iovance BiotherapeuticsN/A -70.93% -55.25%
ImmunityBio -93,761.41%N/A -114.56%

Iovance Biotherapeutics received 554 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 74.47% of users gave Iovance Biotherapeutics an outperform vote while only 13.64% of users gave ImmunityBio an outperform vote.

CompanyUnderperformOutperform
Iovance BiotherapeuticsOutperform Votes
557
74.47%
Underperform Votes
191
25.53%
ImmunityBioOutperform Votes
3
13.64%
Underperform Votes
19
86.36%

In the previous week, Iovance Biotherapeutics had 1 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Iovance Biotherapeutics and 10 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.52 beat Iovance Biotherapeutics' score of 0.12 indicating that ImmunityBio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Iovance Biotherapeutics
3 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ImmunityBio
4 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 10.4% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 83.4% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Iovance Biotherapeutics beats ImmunityBio on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IOVA vs. The Competition

MetricIovance BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.16B$2.55B$4.74B$7.30B
Dividend YieldN/A2.89%5.47%3.98%
P/E Ratio-6.0214.15166.6115.30
Price / Sales2,656.97300.542,442.5080.65
Price / CashN/A143.7331.6127.23
Price / Book4.963.854.564.22
Net Income-$444.04M-$49.20M$101.24M$213.34M
7 Day Performance-5.03%-3.85%-1.34%-0.42%
1 Month Performance-24.63%-11.28%-6.69%-5.10%
1 Year Performance98.25%2.67%8.25%4.76%

Iovance Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBRX
ImmunityBio
0.1145 of 5 stars
$4.92
-6.1%
$5.00
+1.6%
+84.3%$3.33B$620,000.00-4.24628Options Volume
News Coverage
Gap Up
SWTX
SpringWorks Therapeutics
2.5659 of 5 stars
$43.40
+2.1%
$68.00
+56.7%
+79.1%$3.20B$5.45M-8.44305Positive News
APGE
Apogee Therapeutics
1.1443 of 5 stars
$50.66
-4.5%
$71.83
+41.8%
N/A$2.96BN/A0.0091
ACLX
Arcellx
2.7999 of 5 stars
$55.22
-3.1%
$74.17
+34.3%
+31.4%$2.94B$110.32M-37.56130
IMCR
Immunocore
2.4349 of 5 stars
$53.37
-3.9%
$80.55
+50.9%
-9.4%$2.66B$249.43M-46.01497Analyst Report
News Coverage
CGON
CG Oncology
0.6371 of 5 stars
$36.47
-3.1%
$61.75
+69.3%
N/A$2.43B$200,000.000.0061News Coverage
DNLI
Denali Therapeutics
3.7282 of 5 stars
$17.34
-2.8%
$41.22
+137.7%
-36.3%$2.41B$330.53M-16.06445
VCEL
Vericel
0.5827 of 5 stars
$47.52
-2.4%
$46.40
-2.4%
+47.3%$2.30B$197.52M-527.94314Positive News
IMVT
Immunovant
2.6054 of 5 stars
$30.40
-0.2%
$48.00
+57.9%
+85.4%$4.42BN/A-16.52164
BEAM
Beam Therapeutics
3.1272 of 5 stars
$25.70
flat
$41.00
+59.5%
-22.7%$2.10B$377.71M-13.53436Analyst Report

Related Companies and Tools

This page (NASDAQ:IOVA) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners